What Zileuton Treats: Main Uses and Benefits

Zileuton is commonly applied for the long-term prophylaxis and chronic management of asthma. The therapeutic approach is focused on providing continuous control over the underlying disease process.

The therapeutic benefit is relevant in conditions involving inflammatory or irritative processes. Prescribing information outlines its use in key areas.

---

Long-Term Asthma and Symptom Control

This medication is used as a foundational therapeutic option for the long-term management of chronic asthma symptoms. The main therapeutic applications are the long-term prophylaxis and chronic treatment of asthma, in addition to the specialized management of Aspirin-Exacerbated Respiratory Disease (AERD). In these situations, Zileuton supports the patient and may assist with maintaining functional stability of the airways, which in turn contributes to easing the overall symptom load by addressing the potential for exacerbations. It is commonly used when patients experience persistent wheezing, chest tightness, chronic shortness of breath, and recurrent coughing.

“It is commonly used to help manage symptoms that interfere with daily comfort and may assist with maintaining stable airway conditions over time.”

---

Focus: Addressing Chronic Airflow Obstruction Symptoms

Add-on Therapy for Symptom Stabilization

Zileuton is commonly applied as an add-on therapy for patients whose asthma symptoms remain persistent despite using other standard maintenance treatments. This is relevant for patients seeking assistance with the symptomatic burden and may support the patient by easing the need for fast-acting rescue medications. For individuals with AERD, this approach also helps manage chronic nasal manifestations, including severe, persistent nasal congestion and the related deterioration of the sense of smell. This may offer supportive relief when symptoms linked to this specific inflammatory state become more disruptive.

Eligibility Map: Who Can and Cannot Use Zileuton — Official Regulatory Information

The eligibility profile for Zileuton is strictly defined by regulatory authorities based on age, hepatic function, and hypersensitivity status. The medicine is primarily approved for use in adults and children 12 years of age and older.

---

Populations for whom use is allowed (as stated in label):

• Adults and children 12 years of age and older.

Populations for whom use is contraindicated:

• Patients with active liver disease or persistent hepatic function enzyme elevations ge 3 times the Upper Limit of Normal (ge 3 imes ULN).
• Patients with a history of allergic reaction (hypersensitivity) to Zileuton or any ingredient in the formulation.
• Patients in the setting of an acute asthma attack (not indicated for the reversal of bronchospasm).

---

Age-related eligibility rules:

• Pediatric Restriction: Use is not recommended for children younger than 12 years because safety and efficacy have not been established.
• Geriatric Consideration: Females ge 65 years may be at an increased risk of liver enzyme elevations (ALT) and require monitoring.

Condition-specific eligibility rules:

• Renal Impairment: No dosage adjustment is necessary for patients with kidney dysfunction or on hemodialysis.
• Pregnancy Status: Use is conditional; it should be used only if the potential benefit justifies the potential risk, as human data are lacking. For breastfeeding, it is not known if Zileuton is excreted in human milk, requiring a decision to discontinue breastfeeding or discontinue the drug.

Connection to the overall eligibility profile: The regulatory documents establish strict boundaries for Zileuton use, with absolute prohibitions tied to hepatic function and hypersensitivity. Eligibility is limited to patients ge 12 years of age, reflecting the regulatory classification that defines who may use the medicine and under what documented conditions.

Interactions with other medicines and products

Zileuton's official interaction profile is characterized by its documented effect as an inhibitor of the Cytochrome P450 1A2 (CYP1A2) enzyme, a key metabolic pathway in the liver. This inhibition can significantly alter the systemic exposure of co-administered drugs.

---

Exposure-Modifying Interactions (PK Augmentation)

Interacting Product Category	Official Regulatory Statement
Theophylline (Xanthine derivative)	Co-administration results in an approximate doubling of serum concentrations.
Warfarin (Anticoagulant)	Results in a clinically significant increase in prothrombin time (PT).
Propranolol (beta-blocker)	Results in the doubling of Propranolol AUC and increased beta-blocker activity.

These interactions are classified as clinically significant in regulatory documents, which stipulate that close monitoring and subsequent dose management for the affected co-administered agent are necessary.

---

Restrictions and Cautions

Co-administration with Fezolinetant is formally listed as contraindicated. Similarly, the combination with Inhaled Loxapine (Adasuve brand) is officially advised to be avoided. The drug is contraindicated in patients with active liver disease or persistent transaminase elevations ge 3 imes ULN due to the risk of hepatotoxicity. Patients consuming substantial quantities of alcohol are also cited for increased caution. The extended-release formulation requires administration within one hour after morning and evening meals to manage exposure.

Zileuton is a small molecule that functions as a selective, reversible inhibitor of the enzyme 5-lipoxygenase (5-LO). This enzyme is required for the initial committed step in the arachidonic acid cascade, specifically catalyzing the C5 hydroxylation of arachidonic acid to yield 5-hydroperoxyeicosatetraenoic acid (5-HpETE).

Inhibition of 5-LO directly prevents the formation of all leukotriene classes, which are eicosanoid lipid mediators. This results in the suppression of LTB4 production and the cysteinyl leukotrienes ( LTC4, LTD4, and LTE4). The reduction in LTB4 levels limits its intracellular signaling as a chemotactic agent for leukocytes. Concurrently, the diminished levels of cysteinyl leukotrienes curtail their effect on bronchial smooth muscle contraction and increased microvascular permeability. This specific pharmacodynamic action modulates the downstream cellular processes driven by leukotriene signaling.

How to Use Zileuton: Official Administration Guidelines

This section outlines the administration and dosing instructions for Zileuton. Zileuton is for oral use only and is intended for chronic maintenance therapy; it must not be used to treat a sudden, acute asthma attack.

---

Official Dosing Regimens

The total recommended daily dose for adults and children 12 years of age and older is 2400 mg. The frequency and per-dose requirements differ based on the tablet form:

Dosage Form	Per-Dose Amount	Frequency	Timing Rule
Immediate-Release Tablet (600 mg)	600 mg	Four times daily (QID)	May be taken with or without food.
Extended-Release Tablet (600 mg)	Two 600 mg tablets (1200 mg total)	Twice daily (BID)	Must be taken within one hour after morning and evening meals.

---

Administration and Procedural Rules

1. Tablet Integrity: Extended-Release tablets must be swallowed whole and should not be chewed, cut, or crushed. The Immediate-Release tablets may be taken with or without food.
2. Missed Dose: If a dose is missed, do not double the next dose to compensate. The patient should take the next scheduled dose at the correct time.
3. Use During Acute Exacerbations: While Zileuton is for chronic use, therapy should be continued during acute asthma exacerbations.
4. Age Restriction: Safety and effectiveness have not been established in children under 12 years of age, and its use is not recommended for this population.

Research evidence / Overview of studies for Zileuton

---

Evidence for use in Chronic Asthma Management

Research has explored the use of Zileuton in randomized controlled trials (RCTs) involving adults and children aged 12 years and older with chronic asthma. These studies examined outcomes related to respiratory function and symptom control, focusing on conditions characterized by fluctuating or episodic manifestations. Key measured outcomes included changes in forced expiratory volume in one second ( FEV1), a measure of lung function, and the reported frequency of asthma symptoms.

Studies reported how symptoms evolved in the observed populations over defined time intervals. Findings describe patterns observed in these trials concerning measurements of FEV1 and changes in the frequency and severity of asthma episodes compared to control groups. Research highlights changes measured during the study period in the need for rescue medication use. This evidence contributes to understanding symptom patterns in the context of asthma.

---

Long-term studies and follow-up

Research has explored outcomes over defined time intervals, primarily in intermediate-term studies lasting up to six months. Data on very long-term effects beyond this period are less extensive and are often derived from open-label or observational settings. Studies report how symptoms evolved in the observed populations over these extended durations. However, long-term effects on factors such as lung function stability are not fully established, and follow-up durations were limited in some circumstances.

---

Evidence in special populations

Zileuton was observed in studies involving adolescents and older adult populations with asthma. Research has examined whether patterns were observed related to symptom changes in these specific age groups. Data for certain groups remain insufficient, and findings concerning women who are pregnant or breastfeeding are limited. Results apply only to the populations studied, and data for certain groups (e.g., very young children or those with unstable, severe asthma) remain insufficient.

---

What is still uncertain about Zileuton

Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions. Certainty remains low regarding the similarity of long-term effects across all subgroups where data are still emerging. The research is ongoing, but long-term effects are not fully established for all potential outcomes. The evidence highlights what is known—and what is still uncertain—about how the drug was studied in populations with conditions characterized by acute or disruptive episodes.

Key Studies & References

1. GINA Pocket Guide for Asthma Management and Prevention (Contextual guideline reference)

Common questions about Zileuton (FAQ)

---

Q: How quickly can someone expect Zileuton to start working?

Official product information describes the time it takes for Zileuton to be absorbed into the bloodstream. For the immediate-release tablet, the drug typically reaches its highest concentration in the blood within about 1.7 hours after a dose. This measurement indicates the speed of absorption, known as Tmax. This rate of absorption does not, however, directly state when the full clinical effect or benefit of the medicine will be noticed.

Q: Does Zileuton interact with any herbal supplements or vitamins?

Regulatory sources indicate Zileuton is an inhibitor of the CYP1A2 enzyme, a substance in the liver that breaks down many co-administered substances, including caffeine. This means Zileuton may potentially increase the exposure of certain co-administered drugs and substances. Additionally, official information suggests that the herbal supplement St. John's wort may decrease the amount of Zileuton in the body. Regulatory information emphasizes the importance of sharing full information about all co-administered products.

Q: How long does Zileuton stay in the body after the last dose?

The official prescribing information provides the drug’s half-life, which is the time it takes for the concentration of the medicine in the blood to be reduced by half. The average terminal half-life of Zileuton is approximately 2.5 to 3.2 hours.

Q: Is Zileuton available as a generic medicine?

Official regulatory records, such as those maintained by the FDA, indicate that Zileuton is available in a generic formulation. This means versions of the medicine containing the same active ingredient are available for prescription.

Q: Does Zileuton contain any common allergens like gluten or lactose?

While specific allergens like gluten and lactose are not explicitly named in the warning section, official labeling does list the inactive ingredients for the tablet formulations. For example, the extended-release tablet contains components such as colloidal silicon dioxide, mannitol, and microcrystalline cellulose. The review of the full list of inactive ingredients with a healthcare professional is described as an important step to check for personal sensitivities.

Q: What is the general expectation for how long it takes to see the full benefit of Zileuton?

Official product information indicates that the drug is rapidly absorbed into the bloodstream. The immediate-release tablet typically reaches its highest concentration in the blood within about 1.7 hours. This is an official pharmacokinetic measurement of absorption, but the time required to achieve the drug's intended full clinical benefit is a separate measurement that has been explored in clinical trials.

Q: Does Zileuton have a risk evaluation and mitigation strategy (REMS) program?

A Risk Evaluation and Mitigation Strategy (REMS) is a program that regulatory bodies may require for medications with certain serious safety concerns to help ensure the benefits outweigh the risks. Regulatory assessment indicates that Zileuton does not currently have a REMS program in place.

How to Store and Dispose of Zileuton?

Zileuton must be stored strictly according to official regulatory requirements to ensure its stability and safety. The medication should be kept at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F).

Storage Requirements

The medication must be protected from excess heat, moisture, and direct light; do not store it in a bathroom. It is mandatory to keep the tablets in the original container, with the lid tightly closed, and always out of the reach of children. Zileuton should also be kept from freezing.

Disposal

Do not keep outdated or no longer needed medicine. To ensure safe disposal, patients should not discard the medication in household trash or flush it down the toilet unless explicitly instructed to do so. Instead, consult a healthcare professional or pharmacist regarding proper disposal methods for any unused or expired product.